Vaxart’s tablet influenza vaccine performs well in phase I

Vaxart has announced positive safety and immunogenicity data from phase I clinical studies with its tablet-form H1N1 seasonal influenza vaccine candidate. The announcement raises hopes for a simple, painless and user-friendly method for administering flu vaccines in the future. The San Francisco-based biotechnology company says the oral vaccine generated serum anti-haemagglutinin (anti-HA) antibody responses and influenza HA-specific T-cell responses in …